Clinical Trial

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-28; most recent amendment 2025-12-31.
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT07208591
Lead Sponsor Staidson (Beijing) Biopharmaceuticals Co., Ltd
Conditions Acute Respiratory Distress Syndrome (ARDS)
Enrollment 406 participants
Start Date 2025-10-31
Primary Completion 2026-07 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-02